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Abstract
Background:  MeCP2, methyl-CpG-binding protein 2, binds to methylated cytosines at CpG
dinucleotides, as well as to unmethylated DNA, and affects chromatin condensation. MECP2 mutations in
females lead to Rett syndrome, a neurological disorder characterized by developmental stagnation and
regression, loss of purposeful hand movements and speech, stereotypic hand movements, deceleration of
brain growth, autonomic dysfunction and seizures. Most mutations occur de novo during spermatogenesis.
Located at Xq28, MECP2 is subject to X inactivation, and affected females are mosaic. Rare hemizygous
males suffer from a severe congenital encephalopathy.
Methods: To identify the pathways mis-regulated by MeCP2 deficiency, microarray-based global gene
expression studies were carried out in cerebellum of Mecp2 mutant mice. We compared transcript levels
in mutant/wildtype male sibs of two different MeCP2-deficient mouse models at 2, 4 and 8 weeks of age.
Increased transcript levels were evaluated by real-time quantitative RT-PCR. Chromatin
immunoprecipitation assays were used to document in vivo MeCP2 binding to promoter regions of
candidate target genes.
Results: Of several hundred genes with altered expression levels in the mutants, twice as many were
increased than decreased, and only 27 were differentially expressed at more than one time point. The
number of misregulated genes was 30% lower in mice with the exon 3 deletion (Mecp2tm1.1Jae) than in mice
with the larger deletion (Mecp2tm1.1Bird). Between the mutants, few genes overlapped at each time point.
Real-time quantitative RT-PCR assays validated increased transcript levels for four genes: Irak1,
interleukin-1 receptor-associated kinase 1; Fxyd1, phospholemman, associated with Na, K-ATPase;Reln,
encoding an extracellular signaling molecule essential for neuronal lamination and synaptic plasticity; and
Gtl2/Meg3, an imprinted maternally expressed non-translated RNA that serves as a host gene for C/D box
snoRNAs and microRNAs. Chromatin immunoprecipitation assays documented in vivo MeCP2 binding to
promoter regions of Fxyd1, Reln, and Gtl2.
Conclusion: Transcriptional profiling of cerebellum failed to detect significant global changes in Mecp2-
mutant mice. Increased transcript levels of Irak1, Fxyd1, Reln, and Gtl2 may contribute to the neuronal
dysfunction in MeCP2-deficient mice and individuals with Rett syndrome. Our data provide testable
hypotheses for future studies of the regulatory or signaling pathways that these genes act on.
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Background
DNA methylation is one of several strategies cells employ
to regulate gene expression. In mammals, cytosine meth-
ylation at CpG dinucleotides is essential for tissue-specific
gene expression, X-chromosome inactivation, genomic
imprinting and silencing of transposable elements. The
methylation signal is interpreted by a family of proteins
that bind to methylated CpGs and recruit transcriptional
repressor complexes. MeCP2, methyl-CpG-binding pro-
tein 2, was the first identified member of this family [1].
MeCP2 is an abundant nuclear protein that binds prefer-
entially to heterochromatin regions on mouse chromo-
somes [1]. MeCP2 has a methyl-CpG-binding domain
(MBD) that binds to methylated CpG dinucleotides adja-
cent to AT sequences [2]. Chromatin immunoprecipita-
tion (ChIP) with anti-MeCP2 antibodies precipitated a
large number of repetitive sequences as well as gene
sequences [3,4]. In vitro, MeCP2 binds to promoters and
represses transcription of diverse disease-related loci,
including FMR1, H19, CCNA1, BRCA1, and several other
genes [5-8]. Additional functions of MeCP2 may be unre-
lated to mCpG binding: chromatin compaction, chroma-
tin looping, alternative splicing, and nuclear
reorganization [4,9-12].
MECP2 mutations are identified in ~ 90% of cases of clas-
sical Rett syndrome (RTT) [13-15]. RTT (OMIM 312750)
is a neurological disorder characterized by apparently nor-
mal development for the first few months followed by
developmental stagnation and regression, loss of pur-
poseful hand movements and speech, truncal ataxia, ster-
eotypic hand movements, deceleration of brain growth,
autonomic dysfunction and seizures [16-19]. MECP2 is
located at Xq28 and is subject to X inactivation. The clas-
sical RTT phenotype is manifest in heterozygous females
that are mosaics for cells with either normal or mutant/
absent MeCP2 protein. Males with a deleterious MECP2
mutation have no functional MeCP2 protein. Although
apparently normal at birth, they display stagnant postna-
tal development, irregular respiration, central hypoxia
and early death [20]. Currently, there is no effective ther-
apy to prevent the developmental regression, autono-
mous nervous system dysfunction and loss of
communication skills in RTT individuals. Gaining more
information about MeCP2's functions and identifying the
regulatory circuits that are disrupted by MeCP2 deficiency
are essential steps for understanding the pathophysiology
of RTT.
Originally, it was hypothesized that MeCP2 is a master
regulatory protein that prevents inappropriate expression
of a potentially large set of genes, and that in the absence
of MeCP2, the expression of many genes would be altered.
This hypothesis was not confirmed by microarray-based
global expression studies. The numbers of mis-regulated
genes were quite limited in different tissues from RTT
individuals and mouse models with MeCP2 loss-of-func-
tion mutations. The lists of mis-regulated genes from dif-
ferent studies are essentially non-overlapping, and the
search for specific MeCP2-target genes has turned up very
few validated candidates [21-27].
We aimed to extend previous global gene expression stud-
ies in Mecp2 mutant mouse models by focusing on the cer-
ebellum that was excluded in the previous work of Tudor
et al. [23]. Gene expression patterns in the cerebellum are
quite distinct from those in other brain regions in many
mouse strains studied by Nadler et al. [28]. Expression of
Mecp2 increases postnatally and is abundant in the adult
cerebellum [29]. The truncal tremor observed in Mecp2-
deficient mice [30,31] and the ataxia observed in RTT girls
suggest cerebellar pathology. In mutant Mecp2-/Y mice,
the cell bodies of cerebellar granule neurons are smaller
and more densely packed [30]. Postmortem examination
of the cerebella of five RTT females ranging in age from 7–
30 years revealed loss of Purkinje cells, atrophy and gliosis
[32]. These published data provided the rationale for our
study design. To address the possibility of mutation-spe-
cific and developmental time-specific changes, we com-
pared expression changes in males of two different Mecp2-
mutant mouse strains and at three different postnatal time
points.
Consistent with previous studies, we did not detect sub-
stantial up-regulation of a discrete set of genes. However,
we observed moderately increased transcript levels mostly
in 8 wk old mutant mice. For four genes, Irak1, Fxyd1,
Reln, and Gtl2, increased transcript levels were validated
by real-time quantitative RT-PCR. Attempts at replication
of the data on independent samples and in different brain
regions yielded variable results. Physical association of
these genes with MeCP2 was confirmed by chromatin
immunoprecipitation (ChIP) assays that documented
MeCP2 binding to promoter regions of Fxyd1, Reln, and
Gtl2. This study reports, for the first time, cerebellar
expression profiles in Mecp2-mutants and proposes novel
MeCP2 target genes that may contribute to the pathophys-
iology observed in RTT individuals and MeCP2-deficient
mice.
Methods
Mouse breeding and sample collection
Females heterozygous for the J-allele (Mecp2tm1.1Jae) [30]
were obtained from Rudolf Jaenisch and bred to BALB/cJ
males. Females heterozygous for the B-allele
(Mecp2tm1.1Bird) [31] were purchased from the Jackson
Laboratory and were bred to C57BL/6J male mice. Tail
DNA samples were genotyped for Mecp2 and Sry (for sex
determination) as described [33]. Sry  primers: F:
TCCCAGCATGCAAAATACAG; R: TGGTCATGAAACT-BMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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GCTGCTT. Only male mutant mice and their male wild-
type siblings were used, because female heterozygotes are
mosaic for MeCP2 deficiency and have variable expressiv-
ity of the mutant phenotype. For the microarray experi-
ments and technical validation by qRT-PCR, we studied
23 mutants and 25 wild-type J-allele mice, and 32 mutant
and 34 wild-type B-allele mice. For biological validation
by qRT-PCR of a new set of samples, we used 20 mutant
and 16 wild-type B-allele mice. Animals were euthanized
with CO2. Cerebella and forebrains were snap frozen on
dry ice. Total RNA was extracted using TRIzol Reagent
(Invitrogen) and analyzed on a 1.5% agarose gel in MOPS
buffer. RNA was concentrated and purified with YM30
microcon columns (Millipore). The Animal Care Com-
mittee of Stanford University approved all experimental
procedures.
Human brain samples
Brain samples from RTT individuals, including two
hemizygous males with known MECP2 mutations, and
non-RTT controls were obtained from the NICHD Brain
and Tissue Bank for Developmental Disorders (UMB#
1238, 1420, 1748, 1815, 4516, and 4852) and from the
Harvard Brain Tissue Resource Center (#b4160). We
extracted total RNA from frozen frontal cortex using RNA
Stat 60 (Tel-Test) or TRIzol reagent (Invitrogen). All
human materials were obtained and studied under a pro-
tocol approved by the Stanford Human Research Protec-
tion Program.
Expression cDNA microarrays
Microarrays were obtained from the Stanford Functional
Genomics Facility (SFGF) [34]. These arrays contain
42,000 different transcripts that represent over 26,000 dif-
ferent genes. The transcripts vary in size and are PCR prod-
ucts from the RIKEN FANTHOM clone sets and a
consortium of Stanford collaborators. The clone IDs on
the cDNA microarrays are available from SFGF. Further
information on the clones can be found at SOURCE [35].
cDNA labelling and microarray hybridization
For preparation of reference RNA, we used a pool of 100
cerebella collected from wild-type C57BL/6J and BALB/cJ
male mice ranging from P7 to P60 in age. Reference RNA
(20  μg) was reverse transcribed using an anchored
oligo(dT) primer and labeled with Cy3-dCTP using the
CyScribe First-Strand cDNA Labeling Kit (Amersham Bio-
sciences, Catalog # RPN6200). Total RNA (20 μg) from
wild-type samples or mutant samples was reverse tran-
scribed and labeled with Cy5-dCTP. Following purifica-
tion with YM30 microcon tubes, labeled reference cDNA
was combined with either labeled wild-type cDNA or
labeled mutant cDNA. The combined reactions (reference
and wild-type or reference and mutant sample) were
applied to a cDNA microarray. Hybridizations were car-
ried out at 65°C for 14–16 hr in a waterbath or hybridiza-
tion oven. Blocking reagents were added according to the
Brown Lab protocol [36].
Microarray data analysis
Following hybridization, microarrays were washed and
immediately scanned with a GenePix 4000B microarray
scanner (Axon Instruments/Molecular Devices). Auto-
matic and manual quality analysis of array spots was per-
formed with Genepix Pro 4.0. All microarray data were
deposited in the Stanford Microarray Database and nor-
malized by total intensity. The Log (base2) of Red/Green
Normalized Ratio (Mean) for each gene was retrieved and
averaged only if the spot on the microarray was from the
same microtiter plate (LUID – laboratory microtiter well
ID). Genes were centered by the mean. Up to five replicate
microarrays were evaluated for each mutant allele at each
time point. There are 41,000 different spots on each
microarray. Some of those spots are not "good" spots,
meaning they do not pass the Genepix program filter and/
or our manual evaluation. Spots do not pass our filter if
the signal is too low, the spot does not have an even dis-
tribution of signal, or if there are any other experimental
problems that deem the spot of poor quality. Some spots
removed for low signal may imply that the gene is not
expressed. Regardless of the reason, genes were excluded
from our analysis if more than 85% of the spots represent-
ing a particular gene are filtered from our data set across
replicate microarrays. After filtering, the number of genes
that remained in our data set were: J-allele: 2 wk (25,365),
4 wk (30,657), 8 wk (29,774); B-allele: 2 wk (28,939), 4
wk (28,005), 8 wk (26,473). Differentially expressed
genes were defined as genes whose expression is consist-
ently (P < 0.05) altered across microarray experiments.
Paired t-tests (Microsoft Excel) were performed by com-
paring the expression of each gene in a mutant sample to
expression in its wild-type sibling. The data were analyzed
with Microsoft Excel and SAM (Sequence Analysis of
Microarrays) software [37]. Microarrays were centered and
clustered using hierarchical clustering software available
at the Stanford Microarray Database [38,39]. The cDNA
microarray data can be accessed online via the SMD [88]
or via the EBI ArrayExpress [89].
Real-time quantitative RT-PCR (qRT-PCR)
Total RNA (2 μg) was treated with 2U DNase I (Ambion)
and reverse transcribed with random hexamers as primers
and Superscript II (Invitrogen). qRT-PCR was performed
using an ABI 5700 (AME Bioscience) instrument. Melting
curve analysis was performed for each reaction to ensure a
single peak. Amplicons were visualized after electrophore-
sis on a 2% agarose gel to ensure presence of a single
amplicon. Amplification of β-actin,  β  2-microglobulin,
Rps28 and RPS18 transcripts served as RNA controls forBMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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relative quantitation (User Bulletin #2, Applied Biosys-
tems). Mouse primers used (5' – 3'):
Mecp2 (F: TGACTTCACGGTAACTGGGAG; R: TTTCACCT-
GAACACCTTCTGATG),
β-actin  (F: TGACCCTGAAGTACCCCATTGA; R: CCAT-
GTCGTCCCAGTTGGTAAC)
β 2m (F: ACCCGCCTCACATTGAAATCC; R: CGATC-
CCAGTAGACGGTCTTG),
Rps28  (F: TAGGGTAACCAAAGTGCTGGGCAG; R:
GACATTTCGGATGATAGAGCGG),
Irak1  (F: CAGAACCACCACAGATCATCATC; R:
GGCTATCCAAGACCCCTTCTTC),
Fxyd1 (F: TCCATTCACCTACGATTACCACA; R: GAATTT-
GCATCGACATCTCTTGC),
Reln (F: CTGTGTCATACGCCACGAACA; R: GGGGAGGT-
ACAGGATGTGGAT),
Gtl2  (F: GACCCACCTACTGACTGATGAACTG; R:
GTGAAGACACAACAGCCTTTCTCC).
Human primers used (5' – 3'):
FXYD1 (F: AGGGACAATGGCGTCTCTTG; R: CGTAAGT-
GAACGGGTCGTGTT (NM_005031)
RPS18 (F: CTTTGCCATCACTGCCATTA; R: ACACGTTC-
CACCTCATCCTC)
Chromatin Immunoprecipitation (ChIP)
We modified a protocol kindly provided by P. Farnham
[40]. Brains of 4 wk-old male mice were isolated and
minced to small pieces. Cross-linking reactions were per-
formed at room temperature for 15 min in the presence of
1% formaldehyde in PBS. Nuclear extracts were prepared
and chromatin was fragmented by sonication to produce
DNA fragments of an average length between 500 bp and
1000 bp. After pre-cleaning with salmon sperm DNA/pro-
tein A agarose (Upstate), we incubated the nuclear extracts
with anti-MeCP2 antibody (Upstate) at 4°C overnight.
MACs Protein A Micro Beads (Miltenyi Biotec) were
added to the reaction to allow the formation of magneti-
cally labeled immune complexes. We purified the bound
complexes using a microcolumn following the manufac-
turer's instructions. After reversal of cross-links and digest-
ing with proteinase K, we isolated DNA fragments with a
DNA purification kit (Qiagen). We performed 36 cycles of
PCR with primers specific to the first ~ 500–1000 bp of
the gene promoter region or to the DMR at the 5' region
of the Gtl2 gene.
Primer pairs: Fxyd1 (F: GCATGTCCTGCTGTATGTCG; R:
CAGCCAGGGTCAAGAAATGT),  Reln  (F: AAAGGGA-
GATTGGGTGACG; R: ACGTGCTTCTGGATGGTTTC),
Gtl2 – A (F: TCCAACACGAAATTCTGCAA; R: TGCTGGT-
CAACATGAACCTC) amplifying nt 94579–94964 and the
nested primers Gtl2 – B (F: CGGTCCACTAGGGCTTTTT;
R: CCAGGTTTTTAGACCCCAGA) amplifying nt 94645–
94775 of AJ320506.
Results
Mecp2-mutant mice differ in phenotype and expression of 
mutant Mecp2 allele
We examined gene expression in the cerebellum of two
different Mecp2-mutant mouse models. The Mecp2tm1.1Jae
(J-allele) mutant has an in-frame deletion of exon 3 that
codes for half of the MBD [30] (Figure 1A). Therefore, the
expected mutant protein, if present, would be unable to
bind methylated DNA. In contrast, the sequences encod-
ing the transcriptional-repression domain (TRD), nuclear
localization signals and C-terminal WW-binding domain,
all encoded by exon 4, are retained. The second mutant,
Mecp2tm1.1Bird (B-allele), is deleted for exon 3 and the cod-
ing sequence of exon 4 [31]. In this allele, ~ 97% of the
Mecp2-coding sequence is deleted, as well as a small part
of the 3'UTR. No mutant mRNA was detected on North-
ern blot [31].
Asymptomatic females, heterozygous for a Mecp2 muta-
tion and less than 6 months old, were bred to wild-type
males. Offspring were genotyped for Mecp2 and Sry (for
sexing). Cerebellar RNA was extracted from hemizygous
males at mean ages of 2 wk, 4 wk and 8 wk. At 4 wk, 22%
of mutant B-allele mice but none of the J-allele mice were
symptomatic. Differences in body weight were observed
in both sets of mice beginning at 4 wk, with the mutants
being significantly smaller than wild-type littermates. At
the "8 wk" time point, 80% of B-allele mice were sympto-
matic, while the range for J-allele mice extended from
10% at 7 wk to 71% at 9 wk. The most consistent abnor-
mality observed in mutant mice was decreased mobility.
At later stages, they developed tremors and hind-limb
clasping and appeared poorly groomed.
Primers designed to amplify a region of exon 4 did not
detect Mecp2 transcripts in B-allele mice as expected, but
qRT-PCR studies revealed normal levels of the mutant
Mecp2 transcript in 8 wk old mice with the J-allele (Figure
1B). Therefore, while the Mecp2tm1.1Bird B-allele represents
a true null mutation, the Mecp2tm1.1Jae (J-allele) produces
a stable mutant mRNA capable of directing synthesis of an
internally deleted mutant protein that may have retained
functions unrelated to mCpG binding. By using wholeBMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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brain extracts for Western blot analyses, we were unable to
detect the predicted protein product of 309 amino acids
made from the J-allele. All antibodies we tested cross-
reacted with an ~ 55 kD unknown protein in all samples
and, therefore, the putative J-allele product may have
been obscured. Alternatively, it may have been degraded
in the majority of neurons.
Differentially expressed genes in Mecp2-mutant mice
To discover gene expression differences between mutant
and wild-type cerebella, we performed microarray experi-
ments of both mutant strains under the same conditions.
Our microarrays contained 26,000 different cDNA clones
spotted on glass slides (Stanford Functional Genomics
Facility). Reverse-transcribed cDNA samples from either
wild-type or mutant cerebella were hybridized to a cDNA
microarray together with a reference sample consisting of
pooled cerebellum cDNA. By carrying out hierarchical
clustering of the microarray data, we found that several
parameters greatly influenced the clustering. In compar-
ing expression data from B-allele mice at 8 wk of age, lit-
termates tended to cluster more than mutants of different
litters (Figure 2). Clustering data from only the wild-type
control mice illustrate the effects of age, strain back-
ground, and array batch (Figure 3). Therefore, in the final
analysis, we only compared mutant expression arrays to
wild-type arrays of mice that were from the same litter and
only microarrays from the same batch. Pair-wise t-tests
were performed to combine data from different wild-type/
mutant pairs.
Consistent with previous expression microarray studies of
whole brain or other brain regions, we found that loss of
MeCP2 function does not lead to global mis-regulation of
gene expression in cerebellum. Even without correction
for multiple testing, the total number of differentially
expressed genes with a p-value of < 0.05 was not signifi-
cantly greater than would be expected by chance (Table
1). In B-allele mice, the number of genes with increased
expression was slightly greater than would be expected by
chance, but only at the 8 wk time point when more of the
mutant mice used were symptomatic. The majority of
changes reflect an increase of transcript levels, consistent
with a relaxation of gene repression.
To identify genes of potential biological significance, we
studied the datasets from different time points and differ-
ent alleles for common differentially expressed genes
(DEG), but very few consistent differences were detected.
The degree of overlap at 2 wk, 4 wk, and 8 wk for each
Structure and expression of Mecp2 mutant alleles Figure 1
Structure and expression of Mecp2 mutant alleles. A. Genomic structure of Mecp2 mutations. a. Wild-type Mecp2 
gene. MBD, methyl-CpG binding domain; TRD, transcription repression domain. White or hatched: coding sequence. Grey: 
non-coding parts of transcript. Exons 1 and 2 that are alternatively spliced, and intron 2, are not drawn to scale. Horizontal bar 
above exon 4 denotes location of the amplicon analyzed by qRT-PCR (in Figure 1B) b. The Mecp2tm1.1Jae (J-allele) mutant has a 
deletion of exon 3 that encodes the N-terminal half of the MBD. c. In the Mecp2tm1.1Bird (B-allele) mutant, exon 3, the coding 
portion of exon 4 and part of the 3'UTR are deleted. This larger deletion eliminates ~ 97% of the coding sequence. B. Real-
time quantitative RT-PCR analysis of Mecp2 expression in cerebellum. Using primers within the deleted region, Mecp2 
transcript was undetectable in mutant mice with the B-allele, when four wild-type and four mutant samples were compared at 
8 wk. This proves the specificity of the primers. In mice with the J-allele, mean Mecp2 expression was higher in the mutants, 
but this difference was not statistically significant (P = 0.11), when six wild-type and seven mutant samples were compared at 8 
wk.BMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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mutant Mecp2 allele is very small (Figure 4A, Additional
file 1). In male mice with the J-allele, no genes showed
altered expression at all three time points. In B-allele mice,
only one Riken clone (H3142G05) [35] was differentially
expressed at all time points. Expression of this gene, later
identified as Tep1, was increased on microarrays: 1.24,
1.52, and 1.25 fold at 2 wk, 4 wk and 8 wk, respectively.
Tep1, which codes for telomerase-associated protein 1,
was first discovered in Tetrahymena and is conserved from
ciliates to humans. TEP1 is the RNA-binding protein of
the telomerase ribonucleoprotein complex that also con-
tains the catalytic reverse transcriptase subunit and an
RNA component that serves as a template for the synthesis
of telomeric repeats [41]. More recently, TEP1 was also
identified as a protein component of vaults that are ribo-
nucleoprotein complexes localized in the cytoplasm of
cholinergic nerve terminals close to synaptic vesicles [42].
Specifically, TEP1 is required for the stable association of
the vault RNA with the vault complex [43]. Tep1 expres-
sion was not significantly changed in mutant mice with
the J-allele.
A total of 27 genes were differentially expressed at two dif-
ferent time points, four in the J-allele mutants and 23 in
the B-allele mutants (Figure 4A). The gene displaying the
greatest expression change is Gtl2 (Gene-trap locus 2) that
was up-regulated 1.6 fold at 2 wk and 1.7 fold at 8 wk in
B-allele mutants. Increased RNA levels were detected by
two different clones on the cDNA microarrays at 2 wk
(2210008A22) and 8 wk (1110014G20). The sequences
are non-overlapping, but both represent the Gtl2 locus.
Gtl2 is an imprinted gene producing a non-coding RNA of
Hierarchical clustering of microarray data from six mutant/ wildtype sib pairs Figure 2
Hierarchical clustering of microarray data from six 
mutant/wildtype sib pairs. Male B-allele mutants at 8 wk 
of age, when most of them are symptomatic, tended to clus-
ter with their wt sibs rather than with mutants of other lit-
ters. Litters are identified by A – F. The array of the litter B 
wild-type sib did not pass quality control standards.
Hierarchical cluster analysis of microarray data from wild-type sibs at three different ages Figure 3
Hierarchical cluster analysis of microarray data from wild-type sibs at three different ages. Strain background had 
the greatest influence on clustering. BALB/c is the major background of the J-allele mice, while B-allele mice are on a C57BL/6 
background. The effects of array batch, and to a lesser extent, age, are also apparent. We, therefore, compared only microar-
rays from littermates, at the same age and using the same array batch, in our search for differentially expressed genes.BMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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unknown function. The paternally expressed gene Delta-
like 1 (Dlk1) and the maternally expressed Gtl2 gene are
close to each other within an imprinted gene cluster on
distal mouse chromosome 12 [44]. Dlk1 expression was
not significantly changed in either mutant.
Since any expression changes that are relevant for the phe-
notype might be seen in both mutant strains, we deter-
mined the number of common expression changes
between the two strains. In general, there is a low degree of
overlap (39 out of 3285 genes) between DEGs in the B-
and J-allele mutants, and only 15 genes overlap at the
same time points (Figure 4B, Additional file 1). Poten-
tially functionally relevant expression changes were
observed in both mutants for several genes: Smarcb1,
Satb1, Fubp3 and Abt1. Smarcb1 is a component of the
SWI/SNF ATP-dependent chromatin-remodeling com-
plex. Two studies have linked MeCP2 and the SWI/SNF
chromatin-remodeling complex [5,45], although this
connection is controversial [46]. SATB1 (special AT-rich
sequence binding protein 1) is predominantly expressed
in thymocytes and specifically binds to nuclear matrix
attachment regions (MARs) [47]. It is involved in chroma-
tin loop formation [48] and mediates formation of a
higher-order transcriptionally active chromatin structure
in activated T cells [49]. Satb1 is also expressed in spinal
cord and distinct regions of the developing mouse brain
in a mutually exclusive fashion with its close relative Satb2
[50]. Like SATB1, MeCP2 also binds to nuclear matrix-
associated DNA repeat sequences in the human genome,
and the chicken ortholog of MeCP2 is the MAR-binding
protein ARBP [51]. In both mutant mouse models,
increased expression was observed for two transcriptional
activators, Fubp3 and Abt1, at 8 wk and for two other tran-
scriptional regulators, Rab8a and Prdm4, at 8 wk and 2 wk,
respectively (Additional file 1).
Increased expression of Irak1, Fxyd1, Reln, and Gtl2 in 
Mecp2-mutant mice
For further studies, we selected four genes based on a fold
change of at least 1.4 and consistency in the directional
change over the majority of microarrays: Irak1,  Fxyd1,
Reln, and Gtl2 (Table 2). Expression of Irak1, encoding
interleukin-1 receptor-associated kinase 1, was increased
in all mutant/wild-type comparisons at 8 wk in B-allele
mice. In real-time qRT-PCR experiments, Irak1 expression
was increased 3.5-fold in the mutant relative to the wild-
type 8 wk B-allele cerebellum samples and 1.9-fold in the
forebrain (RC and RF, Figure 5). In the microarray data,
Irak1  expression was not significantly altered at other
ages, nor was it altered in J-allele mice. The Irak1 gene is
located only 3 kb distal to Mecp2. Therefore, this expres-
sion change may reflect the altered genomic environment.
For example, an element that negatively influences Irak1
expression could be deleted in the B-allele, but not in the
J-allele that has a much smaller deletion.
Fxyd1 encodes the FXYD domain containing ion transport
regulator 1, also called phospholemman. Fxyd1 expres-
sion was consistently increased in all microarray experi-
ments (average 1.4 fold) of B-allele mice at 8 wk (Table 2).
The results were confirmed by qRT-PCR analysis on the
same cerebellum samples (RC, Figure 5). Biological repli-
cation by qRT-PCR on a different set of B-allele mice
(RC2; 3 wt, 5 mut) yielded more variable results between
litters resulting in large SEM error bars and a p-value of
0.13. Fxyd1 expression in forebain samples from six differ-
ent litters showed no difference between mutant and
wild-type samples, but Fxyd1 expression is normally very
low in forebrain.
Reln, encoding the extracellular signaling molecule reelin,
is highly expressed in the developing cerebellum. Reelin is
essential for proper neuronal lamination and synaptic
plasticity. We found increased Reln transcript levels (1.5
fold) in four microarray experiments of B-allele samples at
2 wk (M, Figure 5). Reln expression was also increased in
qRT-PCR experiments (RC), but this increase is not statis-
tically significant as there was substantial variation among
the samples tested (Figure 3). No difference was seen in
hippocampus when 5 wild-type and 7 mutant samples
were compared (RH, Figure 5).
Table 1: Cerebellum gene expression microarray data
Mutant Age Sib Pairs DEG* DEG Total
(+/y, -/y) up down
J-allele 2 wk 5 292 2 294
4 wk 3 126 105 231
8 wk 5 441 399 840
B-allele 2 wk 3 380 262 642
4 wk 4 423 45 468
8 wk 3 615 234 849
*DEG: Differentially expressed genes with at least a 1.2 fold increase or decrease that are consistently changed for the given mutant and wild-type 
siblings (P < 0.05).BMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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Differentially expressed genes (DEG) in cerebellum microarray study Figure 4
Differentially expressed genes (DEG) in cerebellum microarray study. A. Overlap of DEG at 2 wk, 4 wk, and 8 wk 
time points. For both mutant alleles, genes whose transcripts were either increased (1.2-fold or higher) or decreased (0.8-fold 
or lower) at P < 0.05 are included. Transcripts in the overlap regions are described in Additional file 1. B. Overlap of DEG 
across both mutant alleles at three time points. The same criteria as in Figure 4A were applied. C. Overlap of DEG across 
all ages in both mutant strains. The 39 transcripts include the 15 overlapping DEG from Figure 4B as well as genes that were 
significantly changed at one age in one mutant and at another time point in the other mutant. The list is provided in the Addi-
tional file 1.BMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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Gtl2, encoding an imprinted maternally expressed non-
translated RNA, is the mouse homolog of MEG3, mater-
nally expressed gene 3, in humans. A study evaluating the
transcripts encoded by Gtl2 identified 13 different splice
variants [52]. Our microarray data revealed significantly
increased Gtl2 expression at 2 wk and 8 wk in B-allele
mice (M, Figure 5). By qRT-PCR assays, the expression
increase was present, but not significant in the same sam-
ples (RC) and in forebrain (RF, Figure 5). Cerebellum
studies of a new set of mice (3 wt, 5 mut), however,
showed no difference (RC2, Figure 5).
MeCP2 binds to the promoters of Fxyd1 and Reln and the 
promoter and differentially-methylated region of Gtl2 in 
vivo
To determine if MeCP2 binds directly to the potential tar-
get genes, we performed chromatin immunoprecipitation
(ChIP) assays on brain tissues. ChIP involves cross-link-
ing genomic DNA to proteins that are bound to it. Subse-
quently, DNA-protein complexes are isolated by
immunoprecipitation with a MeCP2 antibody and cross-
links are reversed. The MeCP2 bound sequences are used
as templates for semi-quantitative PCR to determine
whether the gene region of interest is binding to MeCP2
[40].
When we used primers specific for the 500–1000 bp Fxyd1
or Reln promoter regions, ChIP results indicated specific
MeCP2 interaction in normal brain extracts (Figure 6).
Amplification was enriched only in the presence of
MeCP2 antibody (Figure 6, lanes 4). There was no, or
much less, amplification of the DNA fragments when
ChIP was performed either with nuclear extract from
Mecp2-mutant mouse brain (lanes 1), or without MeCP2
specific antibody (lanes 2), or with non-specific antibody
(IgG) (lanes 3). The results suggest that MeCP2 is part of
a complex that is located at the promoter regions of these
genes in normal brain and that this complex may not
form in brain of Mecp2tm1.1Bird mutant mice.
Gtl2 is an imprinted transcript whose maternal-specific
expression is controlled by a differentially-methylated
region (DMR) that overlaps the promoter region. MeCP2
binding was systematically analyzed using overlapping
primer sets, each of which covers 250–400 bp of a region
that contains the Gtl2-DMR (AJ320506, nt 92340–
95350). MeCP2 binding activity was detected upstream of
exon 1 and extending through exon 1 into intron 1
(AJ320506, 93720–95350) (Figure 6). This 1.6 kb region
contains 63 CpG dinucleotides, many of which are differ-
entially methylated.
FXYD1 expression in human brain with MeCP2 deficiency
Recently, Deng et al (2007) [53] identified FXYD1 as a tar-
get of MeCP2 by increased expression in the frontal cortex
of RTT individuals and of Mecp2-mutant mice, with no
changes observed in the cerebellum. While these authors
confirmed by ChIP that MeCP2 binds to the FXYD1 pro-
moter, their expression results were the opposite of our
findings in mouse brain. Therefore, we examined FXYD1
expression in human brain samples from five RTT
females, two males with congenital encephalopathy (CE)
and documented MECP2 mutations, and seven non-RTT
controls (Figure 7). We used real-time quantitative RT-
PCR with the same primers as Deng et al. [53]. We nor-
malized  FXYD1  expression levels to RPS18  expression
rather than to rRNA expression. The ages of the donors
differed only slightly, with controls in their 30 s and RTT
females in their 20 s. The two CE males were between 1
and 2 years old. No MECP2 mutation had been identified
in the single female RTT sample (UMB# 1748) with an
increased FXYD1 transcript, but a brain contusion lesion
was seen on autopsy. Our results do not confirm an
increase in FXYD1 expression in frontal cortex of MeCP2-
deficient humans, and they agree with our data on Mecp2-
mutant mice. If MeCP2 were responsible for silencing
FXYD1 in the forebrain, one would expect to observe a
major increase in hemizygous males with CE who have no
MeCP2 activity at all, as compared to RTT females who are
mosaic for MeCP2-deficient and normal cells.
Discussion
The aim to discover abnormally expressed genes in
MeCP2-deficient mice is two-fold: to reveal direct targets
of MeCP2 modulation and to identify components of
neuronal pathways and circuits that are deregulated in
affected brain regions. The ultimate goals are to under-
stand the pathophysiologic processes that lead to morbid-
ity in RTT and to design rational therapies to prevent or
revert the functional abnormalities. To reduce microarray
data noise caused by cellular heterogeneity of tissues, we
focused on the cerebellum, a part of the brain not previ-
Table 2: Genes with increased expression levels on microarrays in B-allele mutants, supported by qRT-PCR and/or ChIP Data
Gene 
Symbol




Irak1 Interleukin-1 receptor-associated kinase 1 Proinflammatory cytokine response, neuroprotection X A7.3 8 wk 2.2
Fxyd1 FXYD domain-containing ion transport regulator 1 Ion transport regulator for Na, K-ATPase 7 B1 8 wk 1.4
Reln Reelin Neuronal layer formation, cell-cell interactions 5 A3-B1 2 wk 1.5
Gtl2 GTL2, imprinted maternally expressed untranslated RNA Growth suppressor, Host gene for snoRNAs and microRNAs 12 F1 2 wk
8 wk
1.6
1.7BMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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ously studied. We compared expression profiles in two
different MeCP2-deficient mouse strains that differ on the
molecular level, the Mecp2tm1.1Bird  (B-allele) and
Mecp2tm1.1Jae (J-allele). Furthermore, we compared expres-
sion profiles at three postnatal ages that span different
developmental stages in the cerebellum. At two weeks,
granule cells are still mitotic and migrating to their final
position in the internal granule layer. At four and eight
weeks, granule cells are post-mitotic and have begun
forming synapses with neurons in the cerebellum and
other brain regions.
Consistent with previous studies on forebrain and hip-
pocampus samples by Tudor and colleagues [23], we did
not observe major expression changes of a large number
of genes in the cerebellum. MeCP2-deficiency does not
significantly alter the cerebellar transcriptome on a global
scale. This is remarkable given that the vast majority of
cells in the cerebellum are granule cells that had shown
morphological abnormalities in J-allele mice [30]. Any
significant overexpression of genes specifically in granule
cells should have been detectable, as it would not be aver-
aged out by cell type heterogeneity. Our results should
caution investigators who engage in cell-type specific pro-
filing studies. Also, no large (> 3 fold) changes were
detected for any single gene. The changes in cerebellum
transcript levels tended to be small (1.5 – 2 fold), but
increases greatly outnumbered decreases. Overall, a
number of genes with increased transcript levels greater
than expected by chance were observed only in B-allele
mice at 8 wk. There are several possible explanations for
these findings.
First, the mutations are different. While B-allele mice are
null at the Mecp2 locus, the J-allele mutation consists of
an in-frame deletion of exon 3 that produces a stable
mutant transcript. The putative mutant protein, which
lacks the MBD domain, but has an intact nuclear localiza-
tion signal, transcription repression domain and C-termi-
nal region, may have maintained certain functions. Some
evidence has been reported for a truncated MeCP2 protein
in the J allele mice. Luikenhuis et al. [54], saw diffuse
nuclear staining with a MeCP2 antibody and speculated
that this probably arose from the detection of the trun-
cated protein. This interpretation is in line with the origi-
nal report of the J-allele mice [30], where Western blot
showed a smaller band that was interpreted to represent
the truncated protein, even though the wild-type samples
had a protein of apparently the same size, but at a lower
level of intensity. The possibility cannot be excluded,
however, that the diffuse nuclear staining was caused by a
cross-reacting protein that does not localize to DAPI-pos-
itive foci. Using tissue microarrays to study the mosaic
composition of Mecp2-expressing and non-expressing
cells in female mice, Braunschweig et al. [55], reported a
background immunoreactivity with a C-terminal anti-
body in male J-allele mice that was apparently not present
in mice with the B-allele. These results would argue in
favor of the presence of an internally deleted mutant pro-
tein present in the J-allele brain, although the intensity
was rather low.
Second, the mice were on different strain backgrounds: B-
allele mice on C57BL/6 and J-allele mice on a mixed back-
Microarray and qRT-PCR results for select DEGs Figure 5
Microarray and qRT-PCR results for select DEGs. 
Irak1, Fxyd1, Reln and Gtl2 were selected for validation of 
expression changes by qRT-PCR analyses in B-allele mice. 
Cerebellum microarray expression data (M) are compared 
with qRT-PCR data from cerebellum (RC), forebrain (RF) 
and hippocampus (RH). For RC of Irak1, Fxyd1 and Gtl2, the 8 
wk samples from the microarray analysis were used. RC2 
data are derived from an independent set of litters at 7.5 to 8 
wk. Error bars represent SEM. One asterisk indicates P < 
0.05, two asterisks indicate P < 0.001. Irak1 expression was 
markedly increased in the cerebellum of 8 wk B-allele mice 
on microarray (2-fold, P = 0.011, four mutant/wild-type pairs) 
and qRT-PCR (3.5 fold, P < 0.001, four mutant/wild-type 
pairs) as well as in the forebrain of a different set of mice at 
7.5 wk (1.9 fold, P < 0.05, three mutant/five wild-type). Fxyd1 
expression was elevated 1.4-fold on microarrays (P < 0.05, 
five mutant/wild-type sibs) and qRT-PCR (RC) (P = 0.053, 
four mutant/wild-type sibs). The RC2 data (five mutant/three 
wild-type) were more variable and yielded P = 0.16. Reln dis-
played an ~ 1.5 fold increase in expression on microarrays (P 
= 0.03, four mutant/wild-type pairs) and qRT-PCR (P = 0.06, 
five mutant/wild-type pairs) at 2 wk (RC) and was not 
changed in hippocampus (RH). On microarray, Gtl2 expres-
sion was increased at 8 wk, but by qRT-PCR we found highly 
variable Gtl2 expression in cerebellum (RC and RC2). Gtl2 
expression was not significantly increased (P = 0.29, eight 
mutant/eight wild-type) in the forebrain.BMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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ground, mostly BALB/cJ. Our hierarchical clustering data
clearly demonstrated a strong effect of strain background
(Figure 3). Random mixed strain background noise
should be overcome, to some extent, by our comparing
only wild-type and mutant sib-pairs and by including a
sufficiently large number of sib-pairs (16 for the B-allele
and 13 for the J allele).
Third, 80% of the B-allele mice at 8 wk were symptomatic,
while fewer of the J-allele mice were showing symptoms.
When the disease process in the brain is further advanced,
the expression changes may be caused by pathologic
events far downstream of direct MeCP2 action.
Although the global level of gene expression is not signif-
icantly altered, that does not preclude the possibility that
some of the genes may have changed expression levels
that are biologically relevant. Therefore, we focused on
whether differentially expressed genes showed a similar
change in other brain regions and in a different set of mice
(biological validation), which is a more relevant evalua-
tion than "statistical" validation. We chose four genes,
Irak1, Fxyd1, Reln, and Gtl2, whose expression levels were
increased in the most consistent fashion. By ChIP analy-
ses, we show that MeCP2 binds to the promoters of Fxyd1
and Reln and to a differentially methylated region of the
imprinted gene Gtl2 in normal mouse brain, suggesting
that these genes may be direct targets of MeCP2.
Irak1
The interleukin-1 receptor-associated kinase 1 gene
revealed the largest significant expression increase of any
gene, in cerebellum (2.0-fold on microarray and 3.5-fold
on qRT-PCR assays) and in forebrain (1.9-fold), but only
in B-allele mice. Irak1 is located ~ 3 kb downstream of
Mecp2  in the same transcriptional orientation (UCSC
Genome browser, Feb 2006 assembly). This suggests that
a negative regulator of Irak1 could have been lost with the
B-allele deletion, or that the altered local chromatin con-
formation leads to increased Irak1 expression. The less
likely possibility that MeCP2 directly regulates the expres-
Relative FXYD1 expression in human frontal cortex Figure 7
Relative FXYD1 expression in human frontal cortex. 
Quantitative real-time RT-PCR analyses were carried out on 
frozen frontal cortex samples from seven unaffected controls 
(C1 – C7), two MECP2-mutant males with congenital 
encephalopathy (CE) and five females diagnosed with RTT, 
with or without identified MECP2 mutations. The mutant 
samples are identified by their brain bank numbers. FXYD1 
expression was normalized to RPS18, a constitutive ribos-
omal protein gene that is expressed at a similar level in brain. 
To calculate relative fold changes, control sample C4 was 
arbitrarily set at 1. All samples were run in triplicate on the 
same plate.
Chromatin immunoprecipitation (ChIP) analysis of differen- tially expressed genes Figure 6
Chromatin immunoprecipitation (ChIP) analysis of 
differentially expressed genes. Whole brain nuclear 
extracts from 4 wk old wild-type and B-allele mutants were 
used for ChIP. Lane M, 100 bp ladder; lane 1, Mecp2-mutant 
chromatin precipitated with anti-MeCP2 (negative control); 
lane 2, wild-type chromatin precipitated with no antibody 
present; lane 3, wild-type chromatin precipitated with rabbit 
IgG, lane 4: wild-type chromatin precipitated with anti-
MeCP2, lane 5: input DNA, lane 6: no DNA control. The 
precipitated DNA was amplified with primers specific for the 
promoter regions of Fxyd1 and Reln, and for the promoter/
DMR of Gtl2. The Gtl2-B amplicon is located within the Gtl2-
A amplicon. Precipitation with anti-MeCP2 shows enrich-
ment relative to the IgG and no antibody controls, indicating 
that MeCP2 is associated with the designated regions in vivo. 
As negative controls, PCR was performed using primers cov-
ering regions that do not interact with MeCP2 for each ChIP 
reaction (not shown).BMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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sion of Irak1 would assume that the J-allele has main-
tained a negative regulatory function, since Irak1
expression is not increased in J-allele mutants. This allele-
specific difference raises the concern that the increased
Irak1 expression may be responsible for some dysregu-
lated genes in the B-allele mice that are not dysregulated
in the J-allele mice. To identify bona fide MeCP2 targets
we, therefore, focused on genes whose promoters bind
MeCP2 in ChIP assays. Nevertheless, any studies done
with the B-allele mice, at any level, from behavior to his-
tology, should be considered in the light of possible
downstream effects of Irak1 overexpression.
IRAK1 belongs to the ser/thr protein kinase family, pelle
subfamily. The protein is comprised of a death domain in
the N-terminus, a central serine/threonine kinase domain,
and a C-terminal serine/threonine rich region. Once
phosphorylated, IRAK1 recruits the adapter protein PELI1
and causes activation of Toll-like-receptor-mediated intra-
cellular signaling pathways. Three different splice variants
in humans and mice differ in their relative abundance in
brain, and differential splicing of IRAK1 may correlate
with the aging process [56]. Our qRT-PCR assay amplified
all three splice forms. Given the postulated role of MeCP2
in alternative splicing [11], it might be of interest to eval-
uate the relative abundance of the different Irak1 splice
forms in Mecp2-mutant B-allele brain.
Fxyd1
In wild-type mice, Fxyd1 expression increases drastically
from 2 wk to 8 wk in the cerebellum (our microarray
data). In Mecp2 mutant mice, microarray and qRT-PCR
studies revealed a significant increase of Fxyd1 transcripts
at the 8 wk time point in B-allele mutants when compared
to wild-type littermates. ChIP analyses confirmed the
binding of MeCP2 to the Fxyd1 promoter. We, thus, have
identified Fxyd1 as a validated target of MeCP2 binding. In
contrast to a recent report by Deng et al. [53], however,
Fxyd1 transcripts were not increased in the mutant fore-
brain where expression levels are normally very low.
Attempting to replicate the reported studies in humans,
we have used qRT-PCR to measure FYXD1 expression in
frontal cortex from male and female individuals with
MECP2 mutations and unaffected controls. We found no
evidence for increased expression in the mutant samples.
Therefore, our data in humans and mice do not support
the hypothesis that MeCP2 is responsible for keeping
FYXD1/Fxyd1 expression low in the majority of cells of
forebrain. A small increase of expression in a neuronal
subtype could have gone undetected, but the large
increases reported by Deng et al. [53] in RTT frontal cortex
are not confirmed by our results.
The protein product, FXYD1, also called phospholemman
(PLM), is a small molecule with a single transmembrane
domain and a member of the FXYD family of small ion
transport regulators. FXYD proteins regulate Na-K-ATPase
activity in a tissue- and isoform-specific way. Each FXYD
gene is expressed in one or more specific tissues [57].
FXYD1 is a major membrane phosphoprotein in heart
and muscle. In brain, FXYD1 is predominantly found in
the cerebellum, specifically in the molecular layer, in
Purkinje neurons, and in axons traversing the granule cell
layer, as well as in the choroid plexus [58]. The protein
forms a helical structure and inserts into lipid membranes
in a trans-bilayer fashion [59]. FXYD1 tetramers form ion
channels selective for K+, Cl-, and taurine that are physi-
cally associated with the Na-K-ATPase [60]. Recent studies
revealed that FXYD1 also inhibits the cardiac Na+/Ca2+
exchanger (NCX1) [61]. Overexpression of FXYD1 in
adult cardiac myocytes acutely alters contractility as a
function of extracellular Ca+ concentration, and Fxyd1
knock-out mice have cardiac hypertrophy [62]. Alteration
of Fxyd1 expression in the heart of Mecp2-deficient mice
and humans could conceivably contribute to cardiac dys-
function and sudden death.
Another member of the FXYD family, FXYD4/CHIF (cor-
ticosteroid hormone induced factor) was initially isolated
as a glucocorticoid response gene [63]. Interestingly, two
putative MeCP2 target genes, Sgk1 and Fkbp5 are also glu-
cocorticoid-inducible and were found to be upregulated
in 8 wk old B-allele mice studied previously [25]. Further-
more, in the Mecp2308 mouse model of MeCP2 deficiency,
circulating corticosteroid levels were increased in
response to stress, and the gene for corticotropin-releasing
hormone (Crh) was overexpressed in brain regions, lead-
ing to the conclusion that the mutant mice have an
enhanced corticosteroid response to stress via increased
CRH signaling [64]. Future studies should evaluate
whether FXYD1, like FXYD4, is also corticosteroid induci-
ble.
Reln
Our identification of Reln as a primary target of MeCP2 is
supported by the following observations: Reln transcript
levels were increased in microarray and qRT-PCR experi-
ments comparing cerebella from a total of 12 wild-type
and 9 mutant mice. And the expression change was seen
at the earliest time point (2 wk) when all mice were
asymptomatic. No expression change was found in hip-
pocampus. ChIP assay on whole brain documented that
MeCP2 binds to the Reln promoter in normal mice. The
proximal promoter of Reln is highly CpG-rich and meth-
ylated in whole brain extracts [65]. Multiple hypermethyl-
ation sites at the Reln  promoter can be induced by
injection of L-methionine. And in a methionine-induced
model of schizophrenia, MeCP2 was shown to bind to the
Reln promoter [66,67].BMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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Reelin is a large extracellular protein that is produced by
discrete populations of cells in the brain. It acts through
the extracellular milieu on neighboring target cells. Until
recently, the primary function of reelin was thought to
involve regulation of neuronal migration during fetal
brain development, by reelin providing an architectonic
signal for the guidance of migrating neurons [68,69]. Ree-
lin-expressing cells include the Cajal-Retzius (CR) cells in
the cortical marginal zone, that are the first neurons to
express  Mecp2  in development, and cerebellar granule
cells. MeCP2-deficient mice have a thinner cortex and
more densely packed neurons that could result from
migratory defects.
Reln expression continues in the adult, in particular in a
subset of GABAergic neurons of the forebrain, as well as in
the olfactory bulb [70]. Reelin can modulate synaptic
plasticity and enhance long-term potentiation (LTP) in
adult hippocampal cultures [71]. The signaling pathway
that reelin acts on involves two high-affinity binding
receptors, the very low density lipoprotein receptor
(VLDLR) and the apolipoprotein E receptor 2 (ApoER2)
[72]. Binding of reelin to VLDLR and ApoER2 triggers
phosphorylation of the cytoplasmic adaptor protein disa-
bled 1 (Dab1) by Src family kinases, in particular Fyn. This
series of reactions is required for cortical layer formation
and for hippocampal dendrite development [73]. In addi-
tion, cyclin-dependent kinase 5-dependent signals are
required for the function of reelin not only in neuronal
migration but also in synaptic transmission [74]. The ree-
lin signaling pathway is also involved in modulating
learning and behavior [75]. Reelin can regulate NMDA-
type glutamate receptor activity and potentiate calcium
influx through NMDA receptors in neuronal cultures [75].
Sinagra et al. [76] documented a reelin-controlled change
in subunit composition of NMDA glutamate receptors
during maturation. Reelin signaling through ApoE recep-
tors plays an essential role in synaptic plasticity and func-
tion in the adult brain [77].
Interestingly, BDNF, brain-derived neurotrophic factor, a
primary target of MeCP2 [78,79] regulates reelin produc-
tion in cortical neurons. Bdnf -/- mice have elevated reelin
levels in Cajal-Retzius cells. Overexpression of BDNF pro-
duces brain abnormalities similar to the phenotype of
reeler (rl) mutant mice. This phenotype is preserved in
slice cultures of hippocampus [80]. Furthermore, in in
vitro co-culture systems, exogenous reelin caused dispersal
of chain-migrating interneuron precursors in the olfactory
bulb, suggesting that overexpression of reelin may affect
neuronal migration [81].
We hypothesize that Reln overexpression is responsible
for part of the phenotype of MeCP2-deficient mice, and
that this phenotype is caused by abnormal neuronal
migration in the developing brain of MeCP2-deficient
mice and by dysregulation of reelin signaling pathways,
thus disturbing synaptic function, in postnatal brain. To
test this hypothesis, we have initiated genetic interaction
studies. We aim to reduce the level of Reln expression in
the Mecp2 mutant background by crossing rl+/- hetero-
zygous males to Mecp2+/- female mice. We have prelimi-
nary evidence that the onset of morbid phenotypes is
delayed and lifespan prolonged in some of the Mecp2Y/-
;Rln+/- double-mutant mice, when compared to their
Mecp2Y/- ;Rln+/+ littermates.
Gtl2 (gene trap locus 2)
By microarray analysis, we identified Gtl2, called MEG3
(Maternally-expressed gene 3) in humans, as a signifi-
cantly increased transcript in mutant cerebellum samples.
qRT-PCR confirmed increased expression, although not
significant due to large biological variation in different lit-
ters, in cerebellum and forebrain. Gtl2 encodes a mater-
nally expressed imprinted non-translated RNA of
unknown function. Gtl2 is expressed in most tissues, but
most highly in brain. It lies within a cluster of imprinted
genes on chromosome 12 that is conserved on distal 14q
in human. Alternatively-spliced Gtl2 transcripts extend to
include intron-encoded C/D box snoRNAs [82] and
microRNAs [83,84]. Thus, Gtl2 might function as a host
gene for these small RNAs. In our qRT-PCR assays, the
increase in Gtl2 expression in cerebellum was less striking,
but Gtl2 expression was consistently increased in the fore-
brain of Mecp2-deficient mice.
Two previous studies have identified Gtl2 as a possible tar-
get of MeCP2. An expression microarray study on whole
brain of one B-allele mouse revealed a 1.9-fold increase in
Gtl2 expression [25]. Independently, by using a variant of
differential display technology and qRT-PCR confirma-
tion, Kriaucionis and colleagues [27] detected increased
Gtl2 expression in whole brains of B-allele mice. Since the
increase was significant only at late symptomatic stages,
the authors suggested that it may represent a secondary
consequence of the disease pathology. In contrast, our
data show a similar increase in Gtl2 expression at 2 wk and
at 8 wk, albeit detected by two different cDNA clones on
the array. Gtl2 has a CpG-rich promoter region that is
unmethylated on the maternal allele and becomes hyper-
methylated on the paternal allele after fertilization
[85,86]. By ChIP assay, we found that MeCP2 binds in vivo
to this region with binding sites extending from 5' of exon
1 into intron 1, raising the possibility that it may play a
role in silencing of the paternal allele. Alternatively,
MeCP2 may bind to methylated CpG sites on the active
maternal chromosome and thus regulate Gtl2 repression
in certain brain regions or cell types. Future studies of
allele-specific expression levels will address these possibil-
ities.BMC Medical Genetics 2007, 8:36 http://www.biomedcentral.com/1471-2350/8/36
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Considering other previously reported candidate MeCP2
target genes that are represented on our microarrays: Only
Snrp70, reported to be increased by qRT-PCR in whole
brain from late symptomatic B-allele mice (1.44 fold, p =
0.04)[27], showed increased expression (1.5-fold) in cer-
ebellum of 8 wk B-allele mice in our study. None of the
following genes had significant expression changes in cer-
ebellum: Uqcrc1 [27], Bdnf [87], Dlx5 [4], Fkbp5 and Sgk1
[25]. This is not surprising given that some of these genes
may be primarily expressed in other brain regions and/or
only in certain neuronal sub-types. Or transcript levels
may be variable, when expression is modulated by activity
state as for Bdnf [78,79]. Our experience with biological
validation and hierarchical clustering of independent
samples taught us about the mitigating effects of different
sibship identities. We need to consider that the different
mothers are Mecp2+/- heterozygotes, having the genotype
of females with RTT. Although not obviously sympto-
matic yet, their variable X-inactivation status could influ-
ence expression profiles in their offspring.
Conclusion
Cerebellar gene expression profiling of two Mecp2-mutant
mouse models at three postnatal time points revealed no
significant global changes. Irak1, located close to Mecp2,
showed the most significant expression increase, but this
may be specific to the large deletion in B-allele mice. We
identified three novel direct MeCP2 target genes by
increased expression and binding of MeCP2 to their pro-
moters. Variable results in different litters do no preclude
the potential importance of these genes. To evaluate the
contributions of these mis-regulated genes to the synaptic
dysfunction and neuropathologic phenotype observed in
MeCP2-deficient humans and mice, further studies using
higher cytological resolution, laser-capture dissection and
immunohistochemical assays, as well as genetic interac-
tion studies and functional assays of the affected path-
ways, will be needed.
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